Format

Send to

Choose Destination
Cancer Res. 2014 Sep 1;74(17):4796-810. doi: 10.1158/0008-5472.CAN-14-0210. Epub 2014 Jun 24.

Neuronal pentraxin 2 supports clear cell renal cell carcinoma by activating the AMPA-selective glutamate receptor-4.

Author information

1
Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida.
2
Division of Clinical Biochemistry and Immunology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
3
Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida. Division of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida.
4
Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida. copland.john@mayo.edu.

Abstract

Clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney cancer and has the highest propensity to manifest as metastatic disease. Recent characterizations of the genetic signature of ccRCC have revealed several factors correlated with tumor cell migration and invasion; however, the specific events driving malignancy are not well defined. Furthermore, there remains a lack of targeted therapies that result in long-term, sustainable response in patients with metastatic disease. We show here that neuronal pentraxin 2 (NPTX2) is overexpressed specifically in ccRCC primary tumors and metastases, and that it contributes to tumor cell viability and promotes cell migration through its interaction with the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor subunit GluR4. We propose NPTX2 as a novel molecular target for therapy for patients with ccRCC diagnosed with or at risk of developing metastatic disease.

PMID:
24962026
PMCID:
PMC4154999
DOI:
10.1158/0008-5472.CAN-14-0210
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center